Mesothelin as a diagnostic biomarker in endometriosis: A cross-sectional study
Kamil Kiecka1, Aleksandra Zygula2, Anna Sankiewicz3
1Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland; Angelius Provita Hospital, Katowice, Poland.
Purpose:
Endometriosis is a prevalent gynecological condition often requiring invasive procedures for diagnosis. This study aimed to assess mesothelin (MSLN) as a potential non-invasive biomarker by analyzing its levels in peritoneal fluid (PF) and plasma.
Materials/Methods:
In a multicenter cross-sectional study, MSLN concentrations were measured using Surface Plasmon Resonance imaging (SPRi) biosensors in samples from women undergoing laparoscopy for pelvic pain or infertility.
Results:
Significantly higher MSLN levels were observed in the PF of patients with endometriosis compared to controls (mean concentrations: 10.24 vs. 9.39 ng/mL, p = 0.038). The elevation was particularly notable in patients with stage I and II endometriosis compared to the control group (mean concentrations: 10.83 vs. 9.39 ng/mL, p = 0.049). No significant differences were observed in plasma.
Conclusions:
Mesothelin in PF may be considered as a potential biomarker for endometriosis, especially in its early stages. Further studies are needed to confirm its diagnostic value.
